Indiana Patent of the Month – December 2023
Neurodon LLC is targeting cellular stress in a bid to revolutionize medicine. Cellular stress has been found at the root of a wide range of diseases. By targeting this contributor, Neurodon hopes to bring relief and health to patients everywhere. This inventive entity has pioneered a solution that could potentially revolutionize neurological therapies and bring new hope to individuals affected by certain neurological conditions.
At the heart of Neurodon’s latest invention is a novel neurostimulation system, a technological marvel designed to interface with the nervous system. What sets this system apart is its targeted and adaptive approach to neurostimulation, offering a personalized and responsive solution for patients dealing with neurological disorders.
The neurostimulation system capitalizes on advanced algorithms and feedback mechanisms, providing a level of precision and adaptability that marks a significant leap forward in the field. By intelligently adapting to the specific needs and responses of each patient, the system aims to optimize the therapeutic impact while minimizing unwanted side effects.
The potential applications of this neurostimulation system are vast, spanning across various neurological conditions where precise neuromodulation is crucial. From chronic pain management to addressing specific motor control issues, Neurodon’s invention opens doors to more effective and tailored treatment modalities.
Furthermore, the adaptability of the system holds promise for enhancing patient comfort and compliance. The ability to fine-tune the neurostimulation parameters based on real-time feedback can lead to more seamless integration into patients’ daily lives, fostering a more patient-centric approach to neurological care.
As we navigate the complexities of neurological disorders, Neurodon’s innovative neurostimulation system stands out as a beacon of progress. While the full implications and applications are yet to be fully realized, the journey from patent to practice holds the potential to reshape the landscape of neurological treatments and bring about transformative changes in the lives of those affected.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.